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Abstract
Background: Evidence from mice suggests that brain infiltrating immune cells contribute to neurodegeneration, and
we previously identified a deleterious lymphocyte infiltration in Parkinson’s disease mice. However, this remains
controversial for monocytes, due to artifact-prone techniques used to distinguish them from microglia. Our aim was to
reassess this open question, by taking advantage of the recent recognition that chemokine receptors CCR2 and
CX3CR1 can differentiate between inflammatory monocytes and microglia, enabling to test whether CCR2+ monocytes
infiltrate the brain during dopaminergic (DA) neurodegeneration and whether they contribute to neuronal death. This
revealed unexpected insights into possible regulation of monocyte-attracting CCL2 induction.
Methods: We used acute 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) mice and assessed monocyte infiltration by
combining laser microdissection-guided chemokine RNA profiling of the substantia nigra (SN) with immunohistochemistry
and CCR2-GFP reporter mice. To determine contribution to neuronal loss, we used CCR2-deletion and CCL2-
overexpression, to reduce and increase CCR2+ monocyte infiltration, and CX3CR1-deletion to assess a potential implication
in CCL2 regulation.
Results: Nigral chemokine profiling revealed early CCL2/7/12-CCR2 axis induction, suggesting monocyte infiltration in
MPTP mice. CCL2 protein showed early peak induction in nigral astrocytes, while CCR2-GFP mice revealed early but
limited nigral monocyte infiltration. However, blocking infiltration by CCR2 deletion did not influence DA neuronal loss.
In contrast, transgenic astrocytic CCL2 over-induction increased CCR2+ monocyte infiltration and DA neuronal loss in
MPTP mice. Surprisingly, CCL2 over-induction was also detected in MPTP intoxicated CX3CR1-deleted mice, which are
known to present increased DA neuronal loss. Importantly, CX3CR1/CCL2 double-deletion suggested that increased
neurotoxicity was driven by astrocytic CCL2 over-induction.
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Conclusions: We show that CCR2+ monocytes infiltrate the affected CNS, but at the level observed in acute MPTP mice,
this does not contribute to DA neuronal loss. In contrast, the underlying astrocytic CCL2 induction seemed to be tightly
controled, as already moderate CCL2 over-induction led to increased neurotoxicity in MPTP mice, likely due to the
increased CCR2+ monocyte infiltration. Importantly, we found evidence suggesting that during DA neurodegeneration,
this control was mediated by microglial CX3CR1 signaling, which protects against such neurotoxic CCL2 over-induction
by astrocytes, thus hinting at an endogenous mechanism to limit neurotoxic effects of the CCL2-CCR2 axis.
Keywords: Neuroinflammation, MPTP, Dopaminergic neurons, Chemokines, Monocytes, Astrocytes, Microglia, CCL2-CCR2,
CX3CL1-CX3CR1, Parkinson’s disease
Background
Parkinson’s disease (PD) is characterized by dopamin-
ergic (DA) denervation of the striatum and progressive
death of DA neurons in the substantia nigra pars com-
pacta (SNpc) [1]. Although there are familial forms,
most are due to unknown primary causes. With patients
diagnosed when the disease is already well underway,
targeting the symptomatic phase is therefore therapeut-
ically relevant.
Neuroinflammatory processes are present in most neuro-
degenerative disorders, including PD, and while not con-
sidered primary causes, they could contribute to the
symptomatic phase [2]. During CNS neurodegeneration,
neuronal damage leads to activation of microglia and astro-
cytes, which in turn can amplify the neuroinflammatory re-
sponse by chemokine secretion leading to CNS infiltration
of peripheral immune cells. In human PD postmortem SN,
there are still activated microglia and infiltrated lympho-
cytes present [2, 3]. Studies in the acute neurotoxic 1-
methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) mouse
model provided evidence that neuroinflammatory pro-
cesses can indeed contribute to nigral DA neuronal death.
This included genetic deletions of microglial effectors [4]
or suppression of T lymphocytes [3], which both reduced
neuronal loss, suggesting that neuroinflammation in PD
actively participates to neuronal death.
Although presence and role of brain infiltrating periph-
eral lymphocytes have been well analyzed in mouse models
of DA neurodegeneration, the situation for peripheral
monocytes is much less clear and remains highly contro-
versial. Essentially, this is because of the technical challenge
to distinguish microglia (the CNS resident macrophages)
from infiltrating blood monocytes becoming tissue macro-
phages [5, 6]. Of note, CNS infiltrating lymphocytes are
much easier to detect, due to well-established antibodies
working in tissue-sections [3], which are lacking for mono-
cytes. The classic method to determine CNS infiltration of
blood monocytes consists of irradiation followed by bone
marrow transplantation (BMT) using donor green fluores-
cent protein (GFP) mice. However, it has been demon-
strated that this strategy leads, through blood-brain-barrier
damage and flooding of the circulation with hematopoietic
stem cells, to artifact brain infiltration of peripheral im-
mune cells (including monocytes), both in the baseline and
especially during neurodegenerative conditions [7–9].
While several previous studies have assessed the presence
of CNS infiltrating monocytes in the MPTP model of DA
neurodegeneration and reported significant infiltration,
they all used this artifact-prone technique [10–13]. In
addition, none of them assessed whether blocking such
CNS monocyte infiltration would affect death of DA neu-
rons in the SNpc. Thus, they remain silent on actual pres-
ence and role of brain infiltrating peripheral monocytes
during DA neurodegeneration.
A recent reassessment of the cellular expression of
chemokine receptors on microglia and blood monocytes
[14–16] has now provided new tools to readdress this
open question. Chemokines are a large family of around
40 ligands and 20 receptors forming defined ligand-
receptor axes and are implicated in attraction of im-
mune cells to inflamed tissues [17, 18]. Inflammatory-
type (classical) blood monocytes are known to express
the chemokine receptor CCR2, which is required for
their infiltration into inflamed peripheral tissues that ex-
press (in mice) one or several of the three chemokines
CCL2/7/12 [19]. Microglia strongly express the chemo-
kine receptor CX3CR1 (the fraktalkine receptor), which
is important for homeostatic interactions with CX3CL1/
fraktalkine expressing neurons [17]. Of note, CX3CR1 is
in mice also expressed by the (non-classical) patrolling-
type CCR2− monocyte subpopulation, but they are less
prominent than CCR2+ inflammatory-type monocytes
and not the principal monocyte cell type implicated in
inflammation-linked tissue infiltration [20]. In part due
to lack of CCR2 antibodies working in tissue sections, it
has been unclear whether microglia express CCR2. Re-
cently developed fluorescent reporter mice for CCR2
and CX3CR1 have now established that CCR2 is not
expressed by resting or activated microglia, while CCR2+
monocytes express only very low levels of CX3CR1 [16].
Although CCR2 will get downregulated once CCR2+
monocytes have infiltrated the tissue (and became mac-
rophages) [19], a window of CCR2 expression should re-
main [6], especially considering the relative stability of
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cytoplasmic expressed GFP. Thus, CCR2 reporter mice
provide a new tool to reassess brain infiltration of in-
flammatory monocytes without the need for artifact-
prone irradiation/BMT strategies.
Of note, several previous studies have used CCL2 or
CCR2 deletion to assess their role in the MPTP model and
suggested no effect on DA neurodegeneration [21–23].
However, at that time, none of them made a link to brain
infiltrating monocytes but rather suggested the CCL2-
CCR2 axis to be implicated in brain resident reactive
responses, with the actual cell types involved remaining
elusive. Importantly, the only study that used deletion of
the crucial monocyte receptor CCR2 [23], only reported
on DA denervation in the striatum but not on actual death
of DA neurons in the SNpc, using a MPTP regiment too
low to induce actual loss of DA neuronal. The other two
studies only assessed deletion of the ligand CCL2 [21, 22],
but the effects could easily be masked by compensation
through the co-induced CCL7/12 ligands.
Thus, despite significant previous efforts, surprisingly,
the actual questions whether inflammatory CCR2+ mono-
cytes do infiltrate the brain and whether they contribute to
loss of nigral DA neurons in a model of DA neurodegener-
ation, remain unanswered. With the present study, we
used the acute MPTP model of DA neurodegeneration
[24] and applied two direct methods to provide answers to
these two long-standing open questions—transgenic
CCR2-GFP reporter mice to track brain infiltration of in-
flammatory CCR2+ monocytes and CCR2 deletion to
block such potential infiltration and assess its role. This re-
vealed early but limited infiltration of CCR2+ monocytes
into the affected SNpc in MPTP mice, but no direct con-
tribution to death of DA neurons. Complementary to the
analysis of CCR2+ monocyte infiltration, we also deter-
mined the cellular source and regulation of the underlying
induction of the corresponding CCL2/7/12 chemokine li-
gands. This revealed that astrocytes are the main source
for induction of monocyte-attracting chemokines in
MPTP mice. Importantly, by analyzing CCL2 regulation,
we found evidence suggesting that microglial CX3CR1-
signaling controls astrocytic CCL2 induction. This could
protect against astrocytic CCL2 over-induction, which




Mice were kept under a 12-h light/dark cycle and had ad
libitum access to food and water. Animal handling was
carried out according to ethical guidelines and experi-
mental procedures approved by the French MESR Min-
istery (protocol no. #02514.01 to C.S.L.). Mouse lines
used: C57BL/6J (Janvier, France and #000664, JAX,
USA), CCR2-GFP (heterozygous BAC-transgenic mice,
expressing GFP from the mouse CCR2 locus, without
expression of transgenic Ccr2; a kind gift of Dr. Eric G.
Pamer, Sloan-Kettering Institute, New York, USA) [25],
CCR2-KO (#004999, JAX, USA; homozygous knock-out
mice deleted for Ccr2), GFAP-CCL2 (#014095, JAX,
USA; heterozygous transgenic mice, expressing mouse
Ccl2 from the human GFAP promotor), CX3CR1-GFP
(#008451, JAX, USA; homozygous knock-in mice deleted
for Cx3cr1 by introduction of GFP); CX3CR1-KO
(homozygous knock-out mice deleted for Cx3cr1),
CCL2-KO (#004434, JAX, USA; homozygous knock-out
mice deleted for Ccl2). Of note, all the lines were on a
C57BL/6J genetic background, important when using
the MPTP model [24] and showed robust 30% loss of
DA neurons at 7 days after acute MPTP intoxication
(see “Results” section). Genotyping: all primers and con-
ditions were used according to JAX (USA) or for CCR2-
GFP as previously described [25]. Of note, GFAP-CCL2
mice can develop a neurological phenotype at advanced
ages (10–12 months old) due to CNS leukocyte infiltra-
tion [26]. However, at the young ages used for our stud-
ies (3–4 months old), their CNS shows no signs of
pathological neuroinflammation [26].
MPTP model
Upon arrival, mice were acclimated for at least 1 week
before MPTP treatment and kept for the duration of the
treatment in a temperature-controlled (22 °C) and venti-
lated cabinet. For all experiments, the acute MPTP para-
digm was used [24]. Mice received 4 intraperitoneal
(i.p.) injections of either a control saline solution or
MPTP-HCl (20 mg/kg; Sigma) at 2-h intervals and were
kept for 48 h at 28 °C before returning to 22 °C for the
rest of the experiment (up to 14 days). Depending on
the mouse line, MPTP cumulative doses resulted in
mortality rates between 10–30%. All MPTP experiments
were done with 12–16-week-old male mice.
Laser microdissection
The protocol was adapted from [27]. Deeply anesthetized
mice (by i.p. injection of a mixture of ketamine [Virbac/
France] at 100 mg/kg and xylazine [Bayer/France] at
10 mg/kg in 0.9% NaCl) were rapidly perfused with 25 ml
of ice-cold saline (to remove blood from the brain) and
sacrificed by spinal dislocation. The brains were rapidly dis-
sected, frozen in isopentane (−30 °C) and stored at −80 °C.
Fifteen-microliter brain sections were collected at −20 °C
on RNAse-free PEN-membrane slides (Leica) using a cryo-
stat. Slides were immediately frozen in a box with desiccate
on dry ice, stored at −80 °C and used within a week. The
region of the SNpc containing the highest density of DA
neurons was fully collected as consecutive sections. Identifi-
cation of the SNpc region containing the highest density of
DA neurons was done by an adapted rapid Nissl stain to
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prevent RNA degradation. Nissl staining for laser microdis-
section (LMD) was as follows: removal of PEN-slides from
−80 °C, rapid drying of slides using a 1200 W hairdryer
(30 s), EtOH 50% (30 s), EtOH 75% (1 min), EtOH 95%
(10 s), EtOH 100% (15 s), drying (with hairdryer for 15 s),
4% cresyl-violet-acetate (in water with 0.3% glacial acetic
acid) (30 s), 2× H2O (5 s each), EtOH 70% (30 s), EtOH
95% (10 s), 2× EtOH 100% (30 s), and final drying (with
hairdryer for 30 s). Slides were further dried in a dessicator
for 1–5 h before LMD. To isolate the SNpc subregion with
the highest density of DA neurons, LMD was performed at
a ×5 magnification using both a Zeiss PALM Microbeam
and a Leica LMD-7000 system. A total of 50 SNpcs were
microdissected per mouse/sample, and SNpcs were col-
lected into dry RNAse-free 0.5 ml adhesive tube caps
(Zeiss). Twenty milliliters of RLT buffer (with 1% β-
mercaptoethanol, RNeasy Microprep Kit; Qiagen) were
added to the tube cap followed by homogenization (vortex
and pipetting), freezing on dry ice and storing at −80 °C.
RNA extraction
For all LMD samples, RNA was extracted with the
RNeasy Microprep Kit (Qiagen) with DNase treatment
and eluted in 12 μl of RNAse-free water. RNA integrity
(RIN value) and RNA concentrations were assessed on a
Bio-Analyzer (Agilent Technologies) using the Pico
Assay II Chips according to manufacturer’s instructions
and on a NanoDrop (Thermo Fisher). For 50 collected
SNpcs, we obtained around 50 ng of total RNA with a
RIN >7.
TaqMan microfluidic card RT-qPCR
To analyze chemokine expression in laser-microdissected
SNpc regions, we first produced single-stranded cDNA
(High-Capacity cDNA Reverse Transcription Kit/wRNase
Inhibitor; Applied Biosystems) from 50 ng of total RNA
(coming from 50 microdissected SNpc per mouse/sample)
using random hexamers, according to the manufacturer’s
instructions in 20 μl reaction volumes. For reverse tran-
scription (RT), all 36 samples (1 mouse/sample; with 9
control samples and 27 MPTP samples, consisting of 9
MPTP samples for the 2, 4, and 7 day timepoints) were
processed in parallel in a 96 multiwell plate on a Gen-
eAmp PCR System 9700 (Applied Biosystems) with the
following conditions: 25 °C (10 min), 37 °C (120 min), and
85 °C (5 s) followed by cooling to 4 °C. Due to the limited
amount of RNA, linear PCR pre-amplification was used,
followed by TaqMan qPCR on 384-well microfluidic cards.
Pre-amplification was performed with 7.5 μl of the result-
ing 20 μl of cDNA using the TaqMan PreAmp Master
Mix (Applied Biosystems) with a custom-made TaqMan
PreAmp Assay Pool (that contained the TaqMan assays
for all the 96 genes from the custom-made TaqMan qPCR
microfluidic cards) according to the manufacturer’s
instructions in a final reaction volume of 50 μl. Pre-
amplification was performed on a GeneAmp PCR System
9700 (Applied Biosystems) using the following conditions:
95 °C (10 min), 14 cycles—95 °C (15 s), 60 °C (4 min). Re-
actions were stored at −20 °C for a maximum of 1 week.
Custom-made TaqMan qPCR 384-well microfluidic cards
(Applied Biosystems) were designed with the 4 × 96 assay
format, containing 96 individual genes (for singlet ana-
lysis), allowing the processing of 4 samples per array. A
total of 9 cards were used for the 36 samples. Primer/
probe sets were chosen from the Applied Biosystems rep-
ertoire and whenever possible to span an intron. Care was
taken to choose primer/probe sets to amplify from the
middle of the coding sequence and to amplify only small
amplicons (60–100 bp). For the qPCR reactions, 1/5 of
the pre-amplified cDNA was used per mouse/sample, and
qPCR reactions were performed using the TaqMan Gene
Expression Master Mix (Applied Biosystems) according to
the manufacturer’s instructions in a final reaction volume
of 100 μl. This was distributed over 96 wells (4 rows of the
384-well microfluidic card) containing the 96 genes,
resulting in a final reaction volume of 1 μl per micro-well.
The qPCR reaction was performed on the 7900HT Fast
Real-time PCR System (Applied Biosystems) coupled to a
robotic plate loader (Applied Biosystems) with the follow-
ing conditions: 50 °C (2 min), 94.5 °C (10 min), 40 cy-
cles—97 °C (30 s), and 59.7 °C (1 min).
Analysis of TaqMan microfluidic card qPCR
We compared the three different MPTP groups (2, 4, and
7 days after intoxication; n = 9 mice per group, as bio-
logical replicates) to the saline samples (n = 9 mice) and
identified statistical significant fold changes (P < 0.05;
ANOVA with Holm-Sidak post hoc analysis). Data analysis
was performed with SDS RQ Manager 2.3c/DataAssist 2.0
(Applied Biosystems) and qBasePlus (Biogazelle). For
normalization, two reference genes (Gapdh and Hprt1)
were assessed, and Hprt1 was chosen as it did show the
least variation among all the 36 samples (gNORM; Bioga-
zelle, Ghent, Belgium). In addition, we confirmed with one
sample that did not undergo an RT reaction that none of
the 96 primer/probe sets amplified potential genomic con-
taminations. Pre-amplification and qPCR for one SNpc
sample showed that 88/96 genes amplified with Ct values
<30 (as an upper limit for a positive signal) indicating suc-
cessful pre-amplification.
Immunohistochemistry
Deeply anesthetized mice were perfused with 25 ml of sa-
line (with 5 U/ml of heparin), followed by 100 ml of 4%
paraformaldehyde (PFA) to fix the brain tissue. The brains
were dissected out and postfixed at 4 °C for 24 h in 4%
PFA followed by 48 h cryoprotection in 30% sucrose (in
PBS), frozen in isopentane (−30 °C) and stored at −80 °C.
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Perfused brains were sectioned at 20 μm on a freezing
microtome (Leica) (at the midbrain level to collect the
SNpc) and sections stored in PBS (4 °C). Floating sections
were rinsed three times with PBS 0.1 M (5 min) and blocked
for 45 min in PBS, 4% BSA (Sigma), 0.3% Triton X100
(Sigma). Primary antibodies were incubated in PBS/0.1%
Triton X100 for 48 h at 4 °C (under mild agitation) and
washed in PBS. For anti-chemokine antibodies, PBS/0.1%
Triton X100 was used for all washing steps. For the anti-
collagen IV antibody, demasking was used (4 min at 37 °C)
in proteinase-K (10 μg/ml; Sigma) and 0.5% Triton X100.
For immunofluorescence stainings, secondary antibodies
were used for 1 h at room temperature in PBS, followed by
washing in PBS. Sections were mounted on gelatinized
slides, dried, and cover-slipped using Fluoromount-G
(Southern Biotech). For immunohistochemical stainings, be-
fore blocking, endogenous peroxidases were inhibited by in-
cubating sections for 5 min in 0.1 M PBS containing 20%
MetOH and 0.9% H2O2. Biotinylated secondary antibodies
(1/250; rabbit anti-goat IgG and goat anti-rabbit IgG; Vector
Labs) were used for 1 h at room temperature in PBS. After
washing (PBS), sections were incubated for 1 h in Elite Vec-
tastain ABC amplification solution (1/150; Vector Labs)
followed by washing in PBS and TB 0.25 M, and revealed
with 3,3′-diaminobenzidine (DAB; VectorLabs). Sections
were mounted on gelatinized slides, dried, and dehydrated:
2× H2O (30 s), EtOH 70% (30 s), EtOH 95% (30 s), 2×
EtOH 100% (30 s) and 2× Xylene (2 min), then cover-
slipped with Permount (Sigma). Primary antibodies: rabbit
polyclonal antibodies against Iba-1 (1/500; Wako), TH (1/
500; US Biological), GFAP (1/3000; Dako), collagen IV (1/
400; Abcam) and GFP (1/500; Invitrogen); goat polyclonal
against CCL2 (1/200; R&D), CCL12 (1/200; R&D), CXCL16
(1/100; R&D) and CCL7 (1/200; R&D); mouse monoclonal
against TH (1/500; Immunostar); rat monoclonal against
CD11b (1/250; Serotec), and chicken polyclonal against GFP
(1/500; Invitrogen) were used. Secondary antibodies: highly
cross-absorbed Alexa 488 (1/500; Invitrogen; donkey anti-
rabbit, donkey anti-mouse, goat anti-chicken), Alexa 555 (1/
500; donkey anti-goat, donkey anti-rabbit, goat anti-rat) and
Alexa 647 (1/500; donkey anti-mouse) secondaries were
used. Lectin: DyLight 594 Lectin (1/500; VectorLabs) was
used for 1 h at room temperature in PBS.
Image analysis and cellular quantification
All fluorescent stainings were analyzed on a Zeiss
AxioImager microscope using FluoUp software
(Explora Nova, France) and Photoshop CS6 (Adobe,
USA). Conditions for tissue processing, immunostain-
ing, and image capturing were kept constant for all ani-
mals. Quantification of MPTP-induced loss of DA
neurons in the SNpc: DAB-immunostained sections
were analyzed by bright-field microscopy, using a Leica
DM4000 semi-automated microscope equipped with
image analysis software (Mercator; Explora Nova,
France). TH-positive DA neurons were quantified ste-
reologically on ten regularly spaced 20-μm thick sec-
tions (every 10th) covering the whole SNpc (six of
these ten sections contain clear SNpc regions) using
the VisioScan stereology tool [3, 28]. Quantification of
CCR2-GFP+ cells and of CCL2+ cells in the MPTP
affected SNpc was done similarly (DAB-immunostain-
ings and quantified stereologically). Briefly, to estimate
the number of CCR2-GFP+ cells in the entire SNpc at
the peak of infiltration (36 h after MPTP intoxication):
CCR2-GFP+ cells were mainly detected in the rostral-
medial part of the SNpc (on four of six clear SNpc sec-
tions). If in a MPTP treated mouse, we would count ten
CCR2-GFP+ cells on a single SNpc section (bilateral), this
would result in: 10 × 4 × 10 = 400 cells per full SNpc. A
similar strategy was used to count CCL2+ and CCR2-GFP
+ cells in the striatum. For all quantifications, the investi-
gator was blinded to the treatment and genotype groups
during the analysis.
Stereotactic LPS injection
C57BL/6J (n = 3) and CCL2-KO (n = 3) mice (males,
3 months old) were anesthetized with ketamine (66 mg/
kg) and xylazine (6.6 mg/kg) in 0.9% NaCl (i.p.). Mice
were placed on a digital stereotaxic frame (David Kopf
Instruments, USA) and injected with a stainless canula
(10 μl syringe, #1701, 26G; Hamilton, Switzerland) into
the SN (medio-lateral +1.3 mm, antero-posterior
−2.9 mm and dorso-ventral −4,6 mm from the bregma).
One microgram of sterile Escherichia coli LPS (Sigma
L4391; serotype, E.C. 0111:B4) was unilateraly injected
into the SN (0.2 μl/min, 1 μl injected). After injection,
the needle was left for 5 min and removed slowly. After
recovery (2 h/37 °C) kept under standard conditions for
48 h until perfusion.
Statistical analysis
All values were expressed as the mean ± SEM. Differ-
ences in means between two groups were analyzed using
one-way ANOVA followed by All Pairwise Multiple
Comparison Procedures (Holm-Sidak method), or when
data were not normally distributed, with a Dunn test.
Differences in means among multiple data sets were an-
alyzed using one- or two-way ANOVA with time, treat-
ment, or genotype as the independent factors. When
ANOVA showed significant differences, pairwise com-
parisons between means were tested by Holm-Sidak post
hoc analysis. When data were not normally distributed,
a Kruskal-Wallis ANOVA on rank test was used,
followed by pairwise comparison using the Dunn test. In
all analyses, P < 0.05 was considered significant (Sigma-
Stat 4.0, SigmaPlot 11; Systat Software, CA, USA).
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Results
Chemokine RNA profiling in the substantia nigra of MPTP
mice reveals early CCL2/7/12-CCR2 axis induction
As brain infiltration of peripheral immune cells during
neurodegeneration is likely controlled by local induction of
chemokines in the affected brain regions, we first per-
formed global RNA profiling of the full chemokine ligand-
receptor family within the microdissected SNpc during the
course of DA neurodegeneration in MPTP mice. This ap-
proach allowed us not just to identify the chemokine
ligand-receptor axes indicative of monocyte infiltration but
also to compare the kinetics of such potential monocyte in-
filtration with the known infiltration of lymphocytes. We
chose the MPTP mouse model and used an acute intoxica-
tion paradigm [24], as this model has been extensively used
to study contribution of neuroinflammatory processes to
DA neurodegeneration [4, 29, 30], including the deleterious
contribution of infiltrating T lymphocytes [3]. Chemokine
ligands should be induced by local glial cells, with the cor-
responding receptors expressed by peripheral lymphocytes
and monocytes [17]. Due to lack of good tissue antibodies
for many mouse chemokines, we used RNA profiling with
highly specific TaqMan qPCR arrays (for all 37 mouse che-
mokines and 24 receptors) [18] and applied laser microdis-
section (LMD) [27] to isolate only the SNpc, avoiding
dilution effects from the less affected neighboring ventral
tegmental area [28] (Fig. 1a, b). Analysis was done at 2, 4,
and 7 days after MPTP intoxication, corresponding to be-
fore, during, and after the peak of DA neuronal loss, re-
spectively [3, 31]. This model shows early microglial
activation (at 1–2 days), followed by astrogliosis (at 2–
4 days) and leads to stable death of around 30% of DA neu-
rons at 7 days (Additional file 1: Figure S1) [3, 32]. In
addition, infiltrating lymphocytes are present in the af-
fected SNpc already at 2 days [3]. To correlate chemokine
profiles with the overall neuroinflammatory process, we
also assessed additional markers, including for microgliosis,
astrogliosis, and lymphocyte presence.
Results confirmed persistent downregulation of Th from
affected DA neurons in the SNpc and induction of an
early neuroinflammatory response that persisted through-
out the neurodegenerative process (microgliosis: cd68,
cd11c, MHC-II, B2m, Cx3cr1; astrogliosis: Gfap; lympho-
cytes: cd3c, Tbx21) (Additional file 2: Table S1A, C). From
the 37 tested chemokines, 27 showed significant regula-
tions during DA neurodegeneration, while ten were not
expressed or not regulated (Additional file 2: Table S1B).
We could separate the chemokines into four different
temporal expression profiles (Additional file 3: Figure S2
and Additional file 2: Table S1B). (Profile A): ten chemo-
kines showing strong early peak induction at 2 days, then
less strong induction at 4 and 7 days (Ccl2/3/4/7/8/12/22,
Cxcl2/10/11); (Profile B): ten chemokines showing early
but persistent induction (at 2/4 and 7 days) (Ccl5/9/11/19,
Cxcl1/5-6/4/9/14/16); (Profile C): two chemokines show-
ing increased upregulation at the late timepoint (Ccl6,
xCl1), and (Profile D): four chemokines showing downreg-
ulation (Ccl20/28, Ccl17/Cxcl13). In addition, one chemo-
kine (CCL24) showed a mixed regulation (early down,
then upregulated). Interestingly, chemokines with early
peak induction (Profile A), seemed to be almost absent
under control conditions (Additional file 2: Table S1B).
Importantly, for most of the early induced chemokines
(16/20; except for Ccl11/19/22 and Cxcl14), the corre-
sponding receptors were expressed and likewise early in-
duced, suggesting induction of functional chemokine axes
(Additional file 2: Table S1B).
As our primary focus was whether there is nigral
infiltration of monocytes during DA neurodegenera-
tion, we were most interested in the CCL2/7/12-
CCR2 (ligand receptor) axis (Fig. 1c). The major cell
type expressing CCR2 are inflammatory blood mono-
cytes, which are attracted to inflamed tissues by
CCL2/7/12, of which CCL2 (MCP-1) is the best de-
scribed one [19]. Importantly, our RNA results
showed both early induction (at 2 days) of CCL2/7/12
and parallel to it, early induction (at 2 days) of
CCR2. Regarding the peripheral immune cell infiltra-
tion, our RNA screen also revealed strong and early













2 days 4 days 7 days (after MPTP) 
RNA Fold Changes compared to saline controls 
SNpc
SNpc
Laser microdissection of mouse SNpc
A B 
CCR2 37.7 15.8 12.9 
C 
SNpc
Fig. 1 Chemokine RNA profiling in the substantia nigra of MPTP mice reveals early CCL2/7/12-CCR2 axis induction. a–b Laser microdissection (LMD) of
Nissl-stained substantia nigra pars compacta (SNpc) from mouse midbrain tissue sections, used for TaqMan RT-qPCR profiling of the full chemokine family
in MPTP mice. a Showing a SNpc before LMD and b showing multiple SNpcs collected by LMD. (Scale bar; b, 200 μm). c Selected results, showing fold
change (P< 0.05; ANOVA with Holm-Sidak test) inductions (RNA) of the CCL2/7/12-CCR2 (ligand receptor) axis at 2, 4, and 7 days (2d/4d/7d) after acute
MPTP intoxication, suggesting nigral CCR2+ monocyte infiltration. Data are shown as average fold changes compared to saline controls; n= 9 mice per
condition, normalized to Hprt1 (for a full list of results, see Additional file 2: Table S1)
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for the known deleterious infiltration [3] of peripheral
T lymphocytes (CCL3/4/5-CCR1/5, CXCL10-CXCR3,
and CXCL16-CXCR6) (Additional file 3: Figure S2B
and Additional file 2: Table S1B). Interestingly, when
comparing the kinetics of the different chemokine axes,
the monocyte (CCL2/7/12-CCR2) axis showed a rather
early peak induction, while the T lymphocytes axes
showed a more maintained induction (Additional file 3:
Figure S2B and Additional file 2: Table S1B, C).
Thus, our RNA profiling shows early induction of the
monocyte-linked CCL2/7/12-CCR2 axis in the affected
SNpc of MPTP mice.
Astrocytes are the main source for early induction of
monocyte-attracting chemokines CCL2 and CCL7 in the
affected substantia nigra of MPTP mice
Next, we confirmed RNA induction of CCL2/7/12 on
a protein level and determined their precise cellular
source in the MPTP affected SNpc. For our initial
RNA screen, we had to focus on a limited number of
timepoints and chose as an overview, 2/4 and 7 days
after MPTP intoxication. However, since the chemo-
kines, we were most interested in, showed a strong
induction already at 2 days (Profile A; CCL2/7/12,
Fig. 1c and Additional file 3: Figure S2B), it was
possible that the real peak induction happened even
earlier (before 2 days). Thus, to determine protein in-
duction, we expanded our initial timecourse with
three earlier timepoints (12, 24, and 36 h).
Interestingly, we detected induction of CCL2 protein
expression exclusively in the affected SNpc, already at
12 h after MPTP intoxication, which reached a clear
peak at 24 h, followed by less strong expressions at 36 h
and 2 days with no signal at 4 and 7 days (Fig. 2). Im-
portantly, confocal analysis revealed that the CCL2 ex-
pressing cells were not (Iba1+) microglia but (GFAP+)
astrocytes (Fig. 3). Of note, we verified the specificity of
the anti-CCL2 antibodies we used, with CCL2 deleted
mice (Additional file 4: Figure S3). In parallel to CCL2, we
also assessed protein induction of the two other CCR2 li-
gands, CCL7 and CCL12 (Additional file 5: Figure S4). As
for CCL2, we detected CCL7/12 inductions, with a peak
at 24 h, exclusively in cells of the affected SNpc. Interest-
ingly, while CCL7 was astrocytic and not expressed by
microglia, CCL12 (a mouse specific chemokine) was only
induced in microglia (Additional file 5: Figure S4). Of
note, all three chemokines showed comparable vesicular
stainings in MPTP mice, while saline injected control
mice were completely blank (Fig. 2 and Additional file 5:
Figure S4), consistent with the RNA data that showed
strong induction, over almost absent signals in controls
(Additional file 2: Table S1B). A further indication for the
specificity of the vesicular CCL2/7/12 stainings, was our
observation that an unrelated chemokine we tested
for another study, CXCL16, that represents beside
CX3CL1 the only membrane-bound chemokine,
showed not a vesicular but a rather membranous
staining (Additional file 6: Figure S5). In the SNpc,
we only detected intracellular CCL2/7/12 stains, although
extracellular or vessel-associated stains could be possible.
However, such stains are likely to be very weak and risk to
be washed out due to the initial perfusion.
Thus, on a protein level, we found strong early but
transient induction of CCL2/7 in the affected SNpc, and
we revealed that the major source for these CCR2+
monocyte-attracting chemokines were astrocytes.
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G F E 





48h - MPTP 12h - MPTP Control 
Fig. 2 Early but transient CCL2 protein induction within the affected substantia nigra of MPTP mice. a–h Immunofluorescence stainings showing the
timecourse of CCL2 protein induction in the SNpc (dotted white line) of MPTP mice, at 12 h (b, f), 24 h (c, g), and 48 h/2 days (d, h) after acute MPTP
intoxication, compared to saline injected controls (a, e). CCL2 in red and TH (marking DA neurons) in green. While CCL2 is absent in controls (a, e), first
signs of CCL2 induction appear at 12 h (b, f) (arrows), followed by robust induction at 24 h (c, g) (arrows and insets) and reduced induction at 36 h
(data not shown) and 48 h/2 days (d, h) (arrows). CCL2 induction does not colocalize with neuronal TH staining (insets in c and g). No CCL2 induction
was detected at 4 and 7 days (data not shown). (Scale bar; h, 200 μm)
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Transgenic CCR2-GFP reporter mice reveal early but lim-
ited infiltration of CCR2+ monocytes into the affected
substantia nigra of MPTP mice
So far, our results showed messenger RNA (mRNA) in-
duction of the CCL2/7/12-CCR2 axis in the affected
SNpc and on a protein level, astrocytic CCL2/7 induc-
tion. We next sought to determine the presence of nigral
infiltration of CCR2+ monocytes, a controversial ques-
tion that remained open (see “Background”). To avoid
artifact-prone irradiation/BMT strategies [7, 8], we took
advantage of the recently generated BAC-transgenic
CCR2-GFP reporter mice [25]. These mice have been
well established to mark all blood CCR2+/Ly6Chigh in-
flammatory monocytes uniformly with GFP [25].
Thus, we performed a full timecourse analysis to as-
sess CCR2+ monocyte infiltration into the SNpc of
CCR2-GFP mice, at 12, 24, 36 h, and 2, 4, and 7 days
after MPTP intoxication (Fig. 4a–d). Of note, our initial
RNA screen was done at 2/4 and 7 days and showed a
strong CCR2 induction already at 2 days (Fig. 1c). As
above, for the protein induction of the corresponding
ligand CCL2, actual peak CCR2+ monocyte infiltration
could happen earlier than at 2 days—thus, our choice to
include three earlier timepoints (12, 24, and 36 h).
The brains of control CCR2-GFP mice contained only
rare CCR2-GFP+ cells mainly in/around vessels and some
associated with meninges (data not shown). We confirmed
robust DA neuronal loss at 7 days after acute MPTP in-
toxication for this CCR2-GFP reporter line (28% com-
pared to saline controls, P < 0.05, Holm-Sidak method;
actual counts of DA neurons (as means +/− SEM) were:
12,040 +/− 302 for saline, n = 3 mice; 8680 +/− 278, for
MPTP, n = 10). Interestingly, compared to saline injected
CCR2-GFP mice, we observed more frequent presence of
CCR2-GFP+ cells within the affected SNpc of MPTP mice,
already at 24 h, followed by a peak at 36 h, after which
numbers rapidly declined at 48 h and reached baseline
levels at 4 and 7 days (Fig. 4a–d). The morphology of
these CCR2-GFP+ cells was rather roundish/elongated
(Fig. 4b–c and e). Of note, in a recent study analyzing
CNS monocyte infiltration in the multiple sclerosis EAE
model and using similar CCR2 reporter mice, the same
roundish/elongated morphology of infiltrating CCR2+
monocytes was detected [6]. We detected CCR2-GFP+
cells, both closely associated with blood vessels but also
within the parenchyma (Additional file 7: Figure S6). Al-
though at 36 h, CCR2-GFP+ cells were clearly visible in
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Fig. 3 Astrocytes are the main source for early CCL2 induction within the affected substantia nigra of MPTP mice. a–g Immunofluorescence
stainings showing colocalization of CCL2 (red, arrows) with GFAP (green, arrows) positive astrocytes (but not TH positive DA neurons; blue, open
arrow in D’) within the SNpc of MPTP mice at 24 h after intoxication (the peak of CCL2 induction, see Fig. 2). a–d) Overview images of several
CCL2/GFAP double-positive cells (arrows) (with enlargements in a’–d’). e–g Confocal images of CCL2/GFAP colocalization, with an orthogonal view
in (g’). h–j) No colocalization of CCL2 (red, arrows) with Iba1 (green, arrowheads) positive microglial cells (or TH positive DA neurons; blue, see open
arrow in enlargement, j’) within the SNpc of MPTP mice. (Scale bars; d and j, 200 μm; d’ and j’, 40 μm; g, 20 μm)
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number within the full SNpc remained however low,
reaching 340 cells (see also “Methods”) (Fig. 4d). Import-
antly, all of the CCR2-GFP+ cells within the affected SNpc
double-stained for CD11b or Iba1 (classic markers present
on monocytes/macrophages and microglia) (Fig. 4e),
strongly suggesting that they are of myeloid origin and
thus infiltrating CCR2+ monocytes. However, CCR2-GFP+
cells expressed less CD11b or Iba1 than neighboring
microglia (Fig. 4e). A possible explanation could be that
infiltrating CCR2+ monocytes express lower levels of these
markers than fully differentiated tissue macrophages.
In addition to the SNpc containing the DA neuronal cell
bodies, we also analyzed their main target, the striatum.
While we detected early striatal CCL2 induction in MPTP
mice (all colocalized with astrocytes) (Additional file 8:
Figure S7), this was much less prominent than in the
SNpc. Consequently, for CCR2, while we detected a trend
to increased striatal presence of CCR2-GFP+ monocytes in
MPTP mice, this was much less prominent than in the
SNpc and did not reach significance (Additional file 9:
Figure S8A), suggesting that CCR2+ monocyte infiltration
requires the presence of affected neuronal cell bodies or
stronger nigro-striatal CCL2 induction.
Thus, by using direct CCR2-GFP labeling, avoiding
artifact-prone irradiation/BMT strategies, our results
provide strong evidence to answer a long-standing open
question—that there is early brain infiltration of inflam-
matory CCR2+ monocytes during DA neurodegenera-
tion, predominantly in the affected SNpc, but in the
acute MPTP model, the level of infiltration remained
transient and rather limited.
CCR2 deletion suggests that nigral infiltration of CCR2+
monocytes, at the level observed in acute MPTP model
mice, does not contribute to loss of DA neurons
To assess whether the limited nigral infiltration of CCR2+
monocytes in the acute MPTP model contributes to DA
neuronal loss, we used CCR2 deleted mice (CCR2 is re-
quired for peripheral tissue infiltration of inflammatory
CCR2+ blood monocytes) [14, 19]. First, we tested the ne-
cessity of a functional CCL2-CCR2 axis for the observed
nigral infiltration of CCR2+ monocytes in the MPTP model
(Fig. 5a). CCR2−/− mice were crossed with CCR2-GFP re-
porter mice to yield CCR2−/−/CCR2-GFP mice. Indeed,
compared to control CCR2+/+/CCR2-GFP littermates, we
found blockage of MPTP-mediated nigral infiltration of
CCR2-GFP+ cells in CCR2−/− mice (Fig. 5a). Of note, al-
though blockage was almost complete, a few cells
remained, representing background or potentially some
CCR2-independent perivascular cells.
However, when we determined the effect of blocking this

















time after MPTP intoxication
GFP















































Fig. 4 CCR2-GFP reporter mice reveal early but limited nigral infiltration of CCR2+ monocytes during MPTP mediated DA neurodegeneration. a–c
Timecourse analysis of appearance of CCR2-GFP+ cells (stained with anti-GFP antibodies, brown, arrows), at 24 h (b) and 36 h (c) after acute MPTP
intoxication within the SNpc of CCR2-GFP mice and compared to saline injected controls (a). Compared to only very rare CCR2+ cells detectable in
controls, multiple CCR2-GFP+ cells are detected at 36 h, (see magnification insets in b and c). d Quantification of CCR2-GFP+ cells within the SNpc at
12 h (n = 3), 24 h (n = 5), 36 h (n = 4), 48 h/2 days (n = 5), 4 days (n = 4), and 7 days (n = 6) after MPTP intoxication in CCR2-GFP mice (compared to
saline injected controls; CON, n = 3), suggesting early but limited CCR2+ monocyte infiltration, with a peak at 36 h, then returning to baseline levels
after 4/7 days. Counts represent the estimated total of CCR2-GFP+ cells within the entire SNpc (means +/− SEM; n = 3–6 mice per condition; *P = 0.048,
***P < 0.001; Kruskal-Wallis test). e Immunofluorescence stains in the SNpc of CCR2-GFP mice at 36 h after MPTP intoxication, showing colocalization of
CCR2-GFP+ cells with myeloid markers CD11b and Iba1 (insets for magnification), beside resident GFP negative microglia (arrowhead) (Scale bars; C,
200 μm, with 10 μm in insets; E, 10 μm)
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loss at 7 days after acute MPTP intoxication, we did not
find any difference between CCR2 deleted (n = 9) and wild-
type (CCR2+/+) (n = 8) mice (28% loss of DA neurons and
32%, respectively) (Fig. 5b). Actual counts of DA neurons
(as means +/− SEM) were 11,760 +/− 280 (saline, n = 3,
CCR2+/+), 8467 +/− 680 (MPTP, n = 8, CCR2+/+), 12,080
+/− 320 (saline, n = 3, CCR2−/−) and 8214 +/− 600 (MPTP,
n = 9, CCR2−/−).
To our knowledge, this is the first time the effect
of CCR2 deletion on loss of nigral DA neurons in
MPTP mice has been assessed. This provides a clear
answer to our initial question—that brain infiltration
of CCR2+ monocytes does not contribute to loss of
DA neurons, at least not in the acute MPTP model
of DA neurodegeneration.
The question remains whether the level of CCL2 in-
duction and CCR2+ monocyte infiltration in the
MPTP model is representative of human PD, where
DA neurodegeneration is much more progressive. Our
results indicate that either brain infiltrating CCR2+
monocytes do not play per se a role during DA neu-
rodegeneration or that in the acute MPTP model,
their infiltration remains too limited, not sufficiently
high to reveal their actual potential to affect positively
or negatively the ongoing DA neuronal loss. Even
more tempting, but of more fundamental interest, our
findings of early but only transient CCL2 induction
and limited CCR2+ monocyte infiltration, could sug-
gest an endogenous mechanism that protects DA
neurons against too strong induction of CCL2 and
deleterious effects of the CCL2-CCR2 axis. In the fol-
lowing, we have assessed these two possibilities.
Transgenic over-induction of astroytic CCL2 in MPTP mice
leads to increased nigral infiltration of CCR2+ monocytes
and increased loss of dopaminergic neurons, suggesting
a neurotoxic potential of such infiltrating CCR2+
monocytes
The current lack of efficient tools to test whether and to
which level monocytes infiltrate in actual human PD,
combined with the limits of the MPTP model to simu-
late the much more chronic human condition, justify, in
our eyes, to further investigate the role of the CCL2-
CCR2 axis during DA neurodegeneration.
Therefore, we used the MPTP model and asked what
the disease contributing effect of such CCR2+ monocytes
would be, if they would infiltrate the SNpc in higher
numbers. To achieve this, we used well-characterized
transgenic mice that overexpress CCL2 in astrocytes
under the astrogliosis sensitive GFAP promotor [33]. In
mice, baseline GFAP expression in the brain is heteroge-
neous, with only weak expression in the SNpc, but
strong upregulation during MPTP induced neuroinflam-
mation [3] (Additional file 1: Figure S1). Thus, the use of
GFAP-CCL2 mice would lead to increased CCL2 induc-
tion during MPTP-mediated DA neurodegeneration,
which should increase nigral infiltration of CCR2+
monocytes.
First, we confirmed that GFAP-CCL2 mice overexpressed
CCL2 in the region containing the SNpc (Additional file 10:
Figure S9A, D, G). Next, we crossed GFAP-CCL2 mice to
CCR2-GFP reporter and indeed found a significantly in-
creased infiltration of CCR2-GFP+ monocytes specifically
in the affected SNpc during MPTP induced DA neurode-
























































Fig. 5 CCR2 deletion blocks nigral CCR2+ monocyte infiltration in MPTP mice but does not affect loss of DA neurons. a Quantification of the effect of
CCR2 deletion on the number of CCR2-GFP+ cells infiltrating the SNpc of MPTP treated CCR2-GFP mice. Compared to CCR2-GFP mice with normal CCR2
content (CCR2+/+/CCR2-GFP), CCR2 deletion in CCR2-GFP mice (CCR2−/−/CCR2-GFP) leads to blockage of nigral infiltration of CCR2-GFP+ cells (measured
at 24 h after MPTP intoxication). Counts represent the estimated total of CCR2-GFP+ cells within the entire SNpc (individual mice are shown; red bars,
mean; n= 4 mice per condition; **P= 0.004, Holm-Sidak method). b Quantification of the effect of CCR2-deletion on the amount of DA neuronal loss in
MPTP mice. Robust MPTP-induced death of DA neurons is measurable in both wild-type (CCR2+/+, n= 8) and CCR2 deleted (CCR2−/−, n= 9) mice (28 and
32%, respectively, compared to saline controls; **P= 0.002, ANOVA with Holm-Sidak test). However, CCR2 deletion does not affect MPTP-induced death
of DA neurons (n.s., non-significant, P> 0.05). Counts represent the estimated total of TH+ DA neurons within the entire SNpc, 7 days after acute MPTP
intoxication (individual mice are shown; red bar, mean)
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comparing double-transgenic GFAP-CCL2/CCR2-GFP
mice to single-transgenic CCR2-GFP littermates
(Fig. 6a–c and Additional file 10: Figure S9D-I). Of
note, saline-injected GFAP-CCL2/CCR2-GFP mice
only showed rare CCR2-GFP+ cells in the SNpc
(Additional file 10: Figure S9A-C).
To assess the effect on neurodegeneration, we quantified
DA neuronal loss both at 7 days after MPTP-intoxication
but also at 14 days, with the idea that the usually stable
neuronal loss might increase due to CCL2 overexpression
(Fig. 6d). Importantly, we found a significant increase in
DA neuronal loss when comparing mice overexpressing
astrocytic CCL2 (GFAP-CCL2) to non-transgenic litter-
mates at both 7 days (37% loss compared to 26%, respect-
ively) and 14 days (40% loss compared to 29%,
respectively) (Fig. 6d). While we did not observe a further
increase in neuronal loss at 14 days, the difference stayed
stable (Fig. 6d). Actual counts of DA neurons (as means
+/− SEM) were 11,620 +/− 344 (wild-type, saline, n = 5),
8588 +/− 286 (wild-type, MPTP, n = 12, 7 days), 8244 +/−
384 (wild-type, MPTP, n = 10, 14 days), 12,065 +/− 168
(GFAP-CCL2, saline, n = 4), 7574 +/− 194 (GFAP-CCL2,
MPTP, n = 10, 7 days) and 7203 +/− 288 (GFAP-CCL2,
MPTP, n = 12, 14 days).
Thus, increasing the number of CCR2+ monocytes in-
filtrating the affected SNpc, suggested that such mono-
cytes, in principal, have a neurotoxic potential in the
MPTP model and could contribute to DA neurodegener-
ation, but only if they infiltrate in higher numbers than
what is normally present in MPTP mice. We next asked
if there is a control mechanism normally limiting the
underlying astrocytic CCL2 induction.
CX3CR1 deletion in MPTP mice leads to CCL2 over-
induction in the substantia nigra, suggesting control of
astrocytic CCL2 induction by microglial CX3CR1
The above results indicated that a too strong astrocytic
CCL2 induction could increase DA neurodegeneration in
MPTP mice. A tempting question would be to ask,
whether in MPTP mice there is a mechanism that limits
such astrocytic CCL2 over-induction, to protect DA neu-
rons against deleterious effects of the CCL2-CCR2 axis.
Interestingly, our previous results from an unrelated
neurodegenerative condition, age-related macular degen-
eration, suggested that deletion of the chemokine receptor
CX3CR1 led to deleterious actions of the CCL2-CCR2
axis [34]. In turn, CX3CR1 deleted mice are known to
show increased MPTP-mediated loss of nigral DA neu-
rons [30], but the mechanism remains unclear. We hy-
pothesized that this increased neurotoxicity could be
indirectly driven by astrocytic CCL2 over-induction, likely
as a consequence of deregulated reactive responses from
CX3CR1 deleted microglia (the main cell type expressing
CX3CR1 in the CNS).
To test this hypothesis, we assessed CCL2 protein in-
duction in the affected SNpc 24 h after MPTP-
intoxication in both CX3CR1−/− (n = 5) and CX3CR1+/+





















































































Fig. 6 Transgenic over-induction of astrocytic CCL2 in MPTP mice increases nigral CCR2+ monocyte infiltration and loss of DA neurons. a–b Use of
transgenic GFAP-CCL2 mice to enhance MPTP-mediated astrocytic CCL2 induction. Immunohistochemistry with anti-GFP antibodies (brown) shows
increased presence of CCR2-GFP+ cells (arrows) within the MPTP-affected SNpc of GFAP-CCL2/CCR2-GFP double-transgenic mice (b) as compared to CCR2-
GFP single-transgenic littermates (a) (measured at 24 h after MPTP intoxication; insets show enlargements). (Scale bars; b, 200 μm; inset in b, 10 μm). c
Quantification of presence of CCR2-GFP+ cells within the SNpc (24 h after MPTP intoxication) between GFAP-CCL2/CCR2-GFP mice (n= 6) and CCR2-GFP
littermates (n= 4), suggests that enhancing MPTP-mediated astrocytic CCL2 induction increases nigral CCR2+ monocyte infiltration (by 2.7 fold, **P< 0.01,
Dunn’s test). Counts represent the estimated total of CCR2-GFP+ cells within the entire SNpc (individual mice are shown; red bars, mean). d MPTP-induced
DA neuronal loss in GFAP-CCL2 mice and wild-type non-transgenic littermates. Quantification at 7 (n= 12) and 14 days (n= 10) after MPTP intoxication,
shows robust and stable loss of DA neurons in wild-type mice (26 and 29%, respectively, compared to saline injected controls (n= 5); ***P< 0.001, ANOVA
with Holm-Sidak test). While saline injected control GFAP-CCL2 mice (n= 4) have normal numbers of DA neurons, the MPTP-induced DA neuronal loss
compared to wild-type mice is significantly increased in GFAP-CCL2 transgenic mice (*P= 0.01, ANOVA with Holm-Sidak test), both at 7 (n= 10) and 14 days
(n= 12) after MPTP intoxication (37 and 40%, respectively, compared to saline injected controls (n= 4); ***P< 0.001, ANOVA with Holm-Sidak test). Counts
represent the estimated total of TH+ DA neurons within the entire SNpc, 7 and 14 days after acute MPTP intoxication (individual mice are shown; red
bars, mean)
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(saline) controls from both genotypes (Fig. 7a, b). Con-
sistent with our hypothesis, we found three times more
cells inducing CCL2 in the SNpc from CX3CR1−/− than
from CX3CR1+/+ mice (Fig. 7c–e). This increased CCL2
induction remained astrocytic and was not present in
microglia (Fig. 7f–k).
Increased MPTP-mediated dopaminergic neurodegenera-
tion in CX3CR1-deficient mice is driven by CCL2 over-
induction, suggesting that microglial CX3CR1 protects
against neurotoxic actions of the CCL2-CCR2 axis
To assess whether the increased number of astrocytes
inducing CCL2 is directly causative for the more pro-
nounced DA neuronal loss in MPTP intoxicated
CX3CR1 deleted mice, we generated mice deficient for
both CCL2 and CX3CR1. We then determined the effect
on DA neuronal loss 7 days after acute MPTP intoxica-
tion. As reported before [30], we confirmed increased
DA neuronal loss in single CX3CR1 deleted mice
(CX3CR1−/−) when compared to wild-type mice (46%
loss compared to 26%) (Fig. 8). Of note, single CCL2 de-
leted mice (CCL2−/−) did not show any difference in DA
neuronal loss when compared to wild-type mice (30%
loss compared to 26%), expected from our data with
CCR2 deleted mice (Fig. 5b). Importantly, mice deleted
for both CCL2 and CX3CR1 (CX3CR1−/−/CCL2−/−)
showed less MPTP-induced loss of DA neurons than
mice deleted for only CX3CR1 (CX3CR1−/−) (30% loss
compared to 46%), resetting the increased level of DA
neuronal loss observed in CX3CR1 deleted mice to
levels observed in MPTP diseased wild-type mice (Fig. 8).
































































Fig. 7 Deletion of microglial CX3CR1 in MPTP mice leads to over-induction of astrocytic CCL2 in the affected substantia nigra. a–d Immunohistochemistry
with anti-CCL2 antibodies (arrows, brown) shows enhanced induction of CCL2 in the MPTP-affected SNpc of CX3CR1 deleted mice (CX3CR1−/−) (d) as
compared to wild-type littermate controls (CX3CR1+/+) (c) (24 h after intoxication; see insets for enlargements). No CCL2 induction was seen in saline control
animals (a, b). e Quantification of increased numbers of CCL2 expressing cells within the MPTP-affected SNpc in CX3CR1−/− mice (n= 5) as compared to
CX3CR1+/+ littermate controls (n= 6), measured at 24 h after intoxication. Counts represent the estimated total cells within the entire SNpc (individual mice
are shown; red bars, mean; quantification, *P= 0.019, Holm-Sidak method). f–k Immunofluorescence stains of MPTP-affected SNpc 24 h after intoxication,
showing that in CX3CR1 deleted mice, CCL2 induction (f, i; red, arrows) still colocalized with astrocytes (g; GFAP, green, arrows; with confocal view in h) and
remained absent from microglia (j; Iba1, green, arrowheads; with confocal view in k). (Scale bars; d, 100 μm; insets, 20 μm; h and k, 20 μm)
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11,403 +/− 86 (wild-type, saline, n = 3), 8470 +/− 404
(wild-type, MPTP, n = 15); 11,451 +/− 125 (CCL2−/−, sa-
line, n = 3), 8032 +/− 300 (CCL2−/−, MPTP, n = 17);
11,313 +/− 131 (CX3CR1−/−, saline, n = 4), 6077 +/− 422
(CX3CR1−/−, MPTP, n = 13); 11,365 +/− 119 (CX3CR1
−/−/CCL2−/− saline, n = 3) and 7931 +/− 302 (CX3CR1
−/−/CCL2−/−, MPTP, n = 14).
Discussion
We had two aims: On the one hand, to resolve the long-
standing questions whether CCR2+ monocytes infiltrate
the brain in the MPTP model of DA neurodegeneration
and whether they contribute to loss of DA neurons. On
the other hand, and as a consequence of what we found
for monocyte infiltration, to better understand the regu-
lation of the underlying induction of the monocyte-
attracting CCL2.
Our initial screen found early nigral induction of the
CCL2/7/12-CCR2 axis, suggesting monocyte infiltration.
As the microdissection was done on fresh frozen tissues,
the CCR2 mRNA increase might have resulted from
remaining blood monocytes. However, to avoid this, we
have perfused the mice with PBS before tissue collection.
Independent of it, the net effect of increased CCR2 in
the SNpc of MPTP mice remains specific. On a protein
level, CCL2/7 were early induced by nigral astrocytes.
This is noteworthy, as classic markers suggest astroglio-
sis to happen after microgliosis [3, 32]. Thus, astrocytes
seem to react very early and act as the main source for
monocyte-attracting chemokines in this model.
While previous studies have attempted to assess
monocyte brain infiltration in MPTP mice, they are
unconclusive as they used artifact-prone irradiation/
BMT strategies [10–13]. To resolve this, we used CCR2-
GFP reporter mice and found early, but transient, nigral
infiltration of CCR2+ monocytes in acute MPTP mice.
However, infiltration was limited and much lower than
what was expected from irradiation-based studies. This
represents an important finding, as it shows for the first
time, with a direct labeling method, whether or not
CCR2+ monocytes infiltrate the affected SNpc. Although
infiltrating CCR2+ monocytes will ultimately downregu-
late CCR2 [19], due to our exhaustive timecourse ana-
lysis, we do not think to have underestimated their
numbers.
A very recent study also used alternative methods to
assess whether myeloid cells infiltrate in MPTP mice
[35]. While we used the classic acute intoxication para-
digm (four injections during 1 day, [24]), they used the
subchronic MPTP model (one daily injection for 5 days,
[24]). To label infiltrating cells, they used an indirect la-
beling strategy (inducible CX3CR1 reporter mice), which
allowed to mark microglia without peripheral myeloid
cells (due to their higher turnover). By focusing on a sin-
gle timepoint, they reported nigral infiltration of periph-
eral myeloid cells, although the exact monocyte cell type
was not specified. Comparing the two studies—they re-
port rather significant, we rather limited infiltration—is
difficult, due to the different MPTP regiments used, but
the results can be interpreted as complementary, consid-
ering the known differences between the two regiments.
However, the novelity of our study lays in its direct la-
beling strategy, which allowed to assess infiltration of
the most common monocyte subtype, inflammatory-type
CCR2+ cells, as well as in the precise timecourse analysis
for both the nigra and the striatum.
To assess the consequence of the limited nigral infil-
tration of CCR2+ monocytes, we used CCR2 deleted
mice. However, while we blocked CCR2+ cell infiltration,
this did not influence DA neuronal loss in MPTP mice.
Our initial RNA screen revealed early peak induction of
the monocyte chemokine axis, while the lymphocyte

























Fig. 8 During DA neurodegeneration microglial CX3CR1 protects
against neurotoxic CCL2 over-induction by astrocytes. Quantification of
the effect of CCL2 deletion on the known increased MPTP-mediated
neuronal loss in CX3CR1 deleted mice. Loss of DA neurons was assessed
by counting of TH positive DA neurons within the affected SNpc, 7 days
after MPTP intoxication. Counts represent the estimated total cells in the
entire SNpc (individual mice are shown; red bars, mean; quantification,
ANOVA with Holm-Sidak test). Compared to wild-type mice (n= 15; 26%
loss of DA neurons, compared to saline- (n= 3) injected controls; **P<
0.01), CX3CR1 deleted mice (CX3CR1−/−) show increased loss (**P< 0.01)
of DA neurons (n= 13; 46% loss of DA neurons, compared to saline (n=
4) injected controls; ***P< 0.001), while the loss of DA neurons in CCL2
deleted mice (CCL2−/−) (n= 17; 30% loss of DA neurons, compared to
saline- (n= 3) injected controls; **P< 0.01), is not different (P> 0.05) from
wild-type mice. However, mice with CX3CR1−/−/CCL2−/− double
deletions (n= 14; 30% loss of DA neurons, compared to saline (n= 3)
injected controls; ***P< 0.001) show less MPTP-induced loss of DA
neurons than mice deleted for only CX3CR1 (30% compared to 46% loss
of DA neurons; **P< 0.01), resetting the increased level of DA neuronal
loss observed in CX3CR1−/− mice (46% loss) to levels observed in normal
wild-type mice (26% loss)
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is consistent with the transient and limited infiltration of
CCR2+ monocytes (which did not affect DA neuronal
loss), as compared to our previous results of more per-
sistent and prominent T lymphocyte infiltration (which
was neurotoxic, see [3]). Of note, while we found only
limited CCR2+ monocyte infiltration, its peak (at 36 h)
was slightly before the reported nigral lymphocyte infil-
tration (at 48 h, see [3]), suggesting that monocyte infil-
tration happens first. As indicated in the introduction,
CCR2-deletion was previously studied in MPTP mice,
but without link to monocytes, using a MPTP regiment
too low to induce neuronal loss and only striatal DA de-
nervation was analyzed [23]. Of note, while no effect on
striatal denervation was reported, this method is much
less sensitive than counting actual loss of nigral DA neu-
rons. The MPTP model is very aggressive on striatal de-
nervation (up to 80%), while loss of nigral DA neurons
remains moderate (up to 30–40%). Thus, it has been
shown that specific genetic modifications had no pro-
tective effect on striatal denervation but showed signifi-
cant protection on nigral neuronal loss [3, 36].
The abovementioned study [35] in the subchronic
MPTP model suggested that infiltrating peripheral mye-
loid cells contribute to DA neurodegeneration via
CD95L/CD95 (FasL/Fas). Peripheral myeloid cells were
specifically targeted by using irradiation with head pro-
tection, followed by bone marrow transplantation from
mice with myeloid deletion of CD95L [35]. While a so-
phisticated strategy, it nevertheless represents a rather
invasive approach and focused on a specific pathway.
Importantly, the global effect of infiltrating myeloid
cells, or more specifically of infiltrating CCR2+ mono-
cytes, the focus of our question, was not directly ad-
dressed. Of note, our previous results also found a
deleterious FasL/Fas effect, but in the acute MPTP
model, and mediated by infiltrating T lymphocytes [3].
One further study assessed brain infiltrating monocytes in
MPTP mice [37], but the main focus was rather on the en-
teric nervous system. They used clodronate liposomes to
transiently deplete blood monocytes and found a protective
effect on myenteric and no effect on brain DA neurodegen-
eration. However, the MPTP regiment used was not suffi-
cient to induce loss of nigral DA neurons, only striatal
denervation was assessed (see comments above) and mono-
cyte depletion was partial (preferentially phagocytic active
ones). While the study found no striatal infiltration, this was
only indirectly measured via density of microglial/macro-
phage markers. Thus, this study could not answer our ques-
tion regarding the presence and role of brain infiltrating
CCR2+ monocytes on DA neuronal loss. Of note, the study
found a direct MPTP effect on blood monocytes, which was
previously also suggested for lymphocytes [38]. However, it
can be assumed that the primary cause for MPTP neuro-
toxic derives from a direct effect on the DA neurons.
Thus, despite previous efforts, the question of whether
brain infiltrating CCR2+ monocytes do contribute to
neuronal death in a model of DA neurodegeneration,
remained open. We believe that our straight-forward ap-
proach of CCR2-GFP reporter mice and CCR2-deletion
provides now a clear answer: The limited nigral infiltra-
tion of CCR2+ monocytes in acute MPTP mice does not
contribute to loss of DA neurons.
While MPTP mice are a powerful tool to analyze DA
neurodegeneration, it remains a very rapid acting model
compared to progressive human PD. Our results showed
limited infiltration and no effect on neuronal loss in mice.
Actual brain monocyte infiltration in humans (or mice)
might only be present during such longer chronic states.
However, the situation in humans remains elusive, as, in
contrast to infiltrating lymphocytes, the tools to detect in-
filtrating monocytes are lacking. Of note, in the human
blood, the ratio of inflammatory-type (classical/CCR2+)
monocytes to patrolling-type (non-classical/CCR2−) mono-
cytes is much higher than in mice [20], which might influ-
ence the level of a potential brain infiltration during
human disease. Together with recent data suggesting in-
creased serum CCL2 levels and deregulated CCR2+ blood
monocytes responses in PD patients [39, 40], it remains
possible that brain infiltrating monocytes are relevant for
human disease, despite our negative results from the acute
mouse model. Furthermore, although CNS infiltrating
CCR2+ monocytes are assumed to rather aggravate neuro-
degeneration/injury, this seems not that clear-cut: While
they act deleterious e.g., in traumatic brain injury models
[41, 42], they are protective in motor neuron disease ALS
mice [43].
Thus, we used transgenic astrocytic CCL2 overexpres-
sion to increase CCR2+ monocyte infiltration and found
that this increased death of DA neurons in MPTP mice.
While it remains artificial, this suggests that CCR2+
monocytes have, in principal, a neurotoxic potential and
could contribute to DA neurodegeneration. However, in
normal mice, acute MPTP intoxication does not lead to
deleterious high levels of CNS monocyte infiltration.
This raised the question, whether there is a mechanism
that limits the underlying astrocytic CCL2 induction, to
avoid deleterious CCL2-CCR2 axis effects. Interestingly,
based upon our own previous results from age-related
macular degeneration [34, 44], we found evidence sug-
gesting that this involves microglial CX3CR1 signaling.
CX3CR1 deleted mice serve as a model, in which light-
induction leads to photoreceptor degeneration, while
normal mice show less degeneration [44]. Compared to
normal mice, retinal degeneration in CX3CR1−/− mice
was paralleled by increased CCL2 induction and retinal
CCR2+ monocytes infiltration [34]. CCR2 deletion
blocked retinal degeneration, suggesting that CX3CR1
usually represses CCL2 over-induction and recruitment
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of neurotoxic levels of CCR2+ monocytes [34]. Transfer-
ring this to DA neurodegeneration, it is well known that
CX3CR1 deleted mice show increased MPTP-induced
DA neuronal loss [30]. While this has been attributed to
deregulated neuron-microglia interactions, we specula-
ted—based on our question to find regulators of CCL2
induction—that it could indirectly be due to neurotoxic
CCL2 over-induction. While such CCL2 over-induction
could be a simple consequence of increased neurodegen-
eration, when we generated a CX3CR1/CCL2 double de-
letion, we rescued the initial increased neuronal loss in
MPTP mice, indicating that CCL2 over-induction is
causative. Thus, we have found unexpected evidence for
a potential regulation of CCL2 induction by CX3CR1-
signaling. This suggests that during DA neurodegenera-
tion, microglial CX3CR1 protects against astrocytic
CCL2 over-induction, which otherwise would become
deleterious and would increase death of DA neurons.
However, as we base our interpretation solely on the
analysis of single CX3CR1-KO, CCL2-KO, and double
CCL2/CX3CR1-KO mice, potential compensatory effects
[45] could play into the observed result. Thus, our pro-
posed regulation of astrocytic CCL2 induction by micro-
glial CX3CR1, remains of correlative nature.
In the CNS, the most likely CCL2 target are brain in-
filtrating CCR2+ monocytes. When we increased their
infiltration in MPTP mice using transgenic CCL2 over-
induction, death of DA neurons was increased. Although
it remains again purely correlative, this could suggest
that microglial CX3CR1 signaling, by limiting astrocytic
CCL2 over-induction, could protect against neurotoxic
levels of brain infiltrating CCR2+ monocytes. This could
be the reason for the only limited nigral CCR2+ mono-
cyte infiltration we detected in wild-type MPTP mice,
which did not affect loss of DA neurons. However, while
the principal receptor is CCR2, there might be other low
efficiency receptors, which could mediate the neurotoxic
effect of CCL2 over-induction. Likewise, while in the
brain CCR2 is mainly expressed by infiltrating mono-
cytes, other cell types (even neurons) might express low
CCR2 levels (not detected by CCR2-GFP) and mediate
the neurotoxic effect of CCL2 over-induction. Of note,
CCR2 can also be expressed by a (minor) subpopulation
of T lymphocytes (subsets of Treg cells) [46]; however,
all CCR2-GFP+ cells we detected in the affected SNpc
were also positive for CD11b or Iba1, suggesting
monocytes.
Interestingly, CX3CR1−/− microglia are known to pro-
duce higher IL-1β levels after LPS induction [30]. In turn,
IL-1β can induce CCL2 in cultured astrocytes [47], suggest-
ing a possible mechanism for the astrocytic CCL2 over-
induction we detected in CX3CR1 deleted MPTP mice. Of
note, in our initial RNA screen in the SNpc of wild-type
MPTP mice (without CCL2 over-induction), Il1b was
actually included as a general inflammatory marker and
showed a moderate induction (Additional file 2: Table
S1C). Of note, in a mouse model of glioblastoma, CX3CR1
deficiency led to increased CNS infiltration of CCR2+
monocytes into the tumor tissue, and it was suggested that
this could be linked to increased microglial IL-1β, which in
turn could induce CCL2 by tumor cells [48].
The main focus of our analysis was the substantia nigra,
but we have also collected data from the striatum. Inter-
estingly, we found only rare astrocytic CCL2 induction in
the striatum and no evidence for increased striatal pres-
ence of infiltrating CCR2+ monocytes in MPTP mice.
However, this was with normal MPTP mice. Surprisingly,
we have the first evidence that in both transgenic lines
with increased MPTP-induced DA neuronal loss, we
found similar effects in both nigra and striatum: Com-
pared to normal MPTP mice, in CCL2 overexpressing
mice, we found increased presence of striatal CCR2+
monocytes (Additional file 9: Figure S8B), and in CX3CR1
deleted mice, we found clear induction of astrocytic CCL2
in the striatum (Additional file 9: Figure S8C). While this
remains speculative, it could suggest that induction of the
CCL2-CCR2 axis only contributes to DA neurodegenera-
tion, when it is present around both the cell bodies and
the target region of affected DA neurons.
Conclusions
We found that during DA neurodegeneration, there is
early induction of CCL2, the main chemokine to attract
CCR2+ monocytes, and that the major source within the
affected nigra are astrocytes. By using CCR2-GFP reporter
mice and CCR2-deletion, we applied straight-forward
methods to provide answers to two long-standing ques-
tions: In the acute MPTP model of DA neurodegenera-
tion, there is limited nigral infiltration of CCR2+
monocytes and they do not contribute to loss of DA
neurons. However, by analyzing the regulation of the
underlying CCL2 induction, we found that increasing
CCL2 induction became neurotoxic. Importantly, we
found surprising evidence suggesting that during DA neu-
rodegeneration, microglial CX3CR1-signaling protects
against such neurotoxic over-induction of CCL2 by astro-
cytes. This could hint at a mechanism to limit neurotoxic
actions of the CCL2-CCR2 axis, including potentially
neurotoxic high levels of nigrostriatal CCR2+ monocyte
infiltration.
Additional files
Additional file 1: Figure S1. Global neuroinflammation and
neurodegeneration in the substantia nigra of acute MPTP model mice. (A-C)
Immunohistochemical stainings (anti-TH; brown) of DA neuronal degeneration
at 2d (B) and loss at 7d (C) after acute MPTP intoxication in wild-type mice
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(C57BL/6J). Quantification shows the expected stable loss of around 30% of
DA neurons (11,680 +/− 240, saline, n= 3; 8410 +/− 440, MPTP, n= 10) (28%
loss; P< 0.05, Holm-Sidak method). Immunofluorescence stainings of (D-F)
microglial activation (Iba1, red) in the SNpc during MPTP-mediated DA neuro-
degeneration (TH, green), showing clear signs of microglial reactivity already at
2 days after MPTP intoxication (before the peak of DA neuronal loss, at 4 days)
and which is further increased until 7 days (after the peak of DA neuronal loss,
when neuronal death has reached a stable level). (G-I). Astroglial activation, as
measured by GFAP activation (GFAP, red), is delayed compared to microglial
activation, only getting strongly induced between 2–7 days after MPTP intoxi-
cation. (Scale bar: F, 200 μm). (PDF 3173 kb)
Additional file 2: Table S1. RNA profiling of chemokines in the laser-
microdissected substantia nigra of the MPTP mouse model. Shown are results
from the RT-qPCR profiling of 96 genes using TaqMan 384-well microfluidic
cards, to assess all 61 chemokine family members (37 ligands, 24 receptors) as
well as 32 other selected neuroinflammation-linked genes, normalized to
Hprt1. RNA profiling was done in laser-microdissected SNpc at 2, 4, and 7 days
after acute MPTP intoxication in adult 12 weeks old C57BL/6J males and
compared to saline-injected controls (n= 9 mice per condition; as biological
replicates). qPCR results are shown as normalized and averaged fold-changes
(FC) to saline controls. In addition, the raw averaged Ct values of both the
control and the 2 days (MPTP) samples are shown. Ct values of >30 are called
absent (Abs). Only FC values that are statistically significant (P< 0.05; qBasePlus,
Biogazelle) are indicated. Of note, the large FC values can be explained by
both the enrichment provided by the LMD and the often very low expression
in baseline control conditions. (nc, expressed but no significant change and
N.D., non-determined) (* asterisks mark unclear corresponding receptors;
Griffith et al. 2014). (PDF 163 kb)
Additional file 3: Figure S2. RNA profiling of the full chemokine family in
the laser-microdissected substantia nigra of MPTP mice. (A) Representative
example of a RNA integrity analysis of RNA isolated from laser-microdissected
SNpc regions (50 per mouse, resulting in 50 ng of total RNA) of fresh frozen
Nissl-stained sections and showing sufficient quality RNA for qPCR analysis (RIN
>7; BioAnalyzer, PicoAssay II). (B) Results show all the chemokines (ligands only)
found to be regulated (TaqMan RT-qPCR arrays; at 2, 4, and/or 7 days after
acute MPTP intoxication) in the SNpc during DA neurodegeneration (27 of the
37 chemokines tested). Four regulation profiles (Additional file 2: Table S1B) can
be distinguished: (“profile A”): 10 chemokines showing strong early peak
induction at 2 days, then less strong induction at 4 and 7 days (Ccl2/3/4/7/8/12/
22, Cxcl2/10/11); (“profile B”): 10 chemokines showing early but persistent i-
nduction (at 2/4 and 7 days) (Ccl5/9/11/19, Cxcl1/5-6/4/9/14/16); (“profile C”): 2
chemokines showing increased upregulation at the late timepoint (Ccl6, xCl1),
and (“profile D”): 4 chemokines showing persistent (Ccl20/28) or late
downregulation (Ccl17/Cxcl13). In addition, one chemokine (CCL24) showed a
mixed regulation (early down, then upregulated) (Additional file 2: Table S1B).
(PDF 505 kb)
Additional file 4: Figure S3. CCL2 deleted mice confirm high specificity
of the used anti-CCL2 antibody. (A-D) Immunofluorescence stainings of LPS-
injected midbrain region (48 h after injection, known to produce a strong
neuroinflammatory reaction which induces CCL2) to assess anti-CCL2 antibody
specificity. (A, C) Results show strong CCL2 positive signal (red), partially
colocalizing with astrocytes (GFAP, green; inset in C) in wild-type mice (CCL2
+/+), while this CCL2 signal is completely absent in CCL2 deleted mice (CCL2
−/−) (B, D), demonstrating specificity of the anti-CCL2 antibody used. (Scale bars;
C, 200 μm; C’, 50 μm). (PDF 3822 kb)
Additional file 5: Figure S4. Induction of the additional two CCR2
ligands, astrocytic CCL7 and microglial CCL12, within the affected substantia
nigra of MPTP mice. (A-F) Immunofluorescence stainings to show that CCL7
(a ligand for CCR2, like CCL2) (red) is not induced under control saline
conditions in the SNpc (dotted white line) (A, D) but gets induced (red,
arrows) 24 h after MPTP intoxication (peak induction) in selected cells, that
are not microglia (Iba1, green; arrowheads; with enlargement in C’) (B, C),
but astrocytes (GFAP, green, arrows) (E-F) (with a confocal orthogonal view
in F’). (G-L) Immuno stainings to show that CCL12 (a ligand for CCR2, like
CCL2) (red) is not induced under control saline conditions in the SNpc
(dotted white line) (G) but gets induced (red, arrows) 24 h after MPTP
intoxication (peak induction) in microglia (H-I) (Iba1, green; with
enlargements in I’). This is also shown using confocal analysis (J-L). (Scale
bars; F, I, 200 μm; C’, I’, 40 μm; F’, L, 20 μm). (PDF 4791 kb)
Additional file 6: Figure S5. Immunostaining characteristics of secreted
(CCL2/12) and membrane-bound (CXCL16) chemokines identified in the
affected substantia nigra of MPTP mice. (A-I) Immunofluorescence stainings
to provide support for the specificity of the identified vesicular staining-
patterns detected for the secreted chemokines CCL2 (red, arrow) in astrocytes
(A-C) (GFAP, green; with confocal analysis in C’) and CCL12 (red, arrows) (D-F)
in microglia (Iba1, green; TH, blue; with confocal analysis in F’), by comparing
to the membranous staining-pattern detected for the membrane-bound
chemokine CXCL16 (G-I) in microglia (Iba1, green; TH, blue; with confocal
analysis in I’). (Scale bars; C, F, I, 20 μm). (PDF 1781 kb)
Additional file 7: Figure S6. CCR2+ monocytes infiltrating the affected
substantia nigra in MPTP mice are present both perivascular and
parenchymal. (A-F) Immunofluorescence stainings within the SNpc (anti-TH,
blue) of CCR2-GFP mice, 24 h after MPTP intoxication to show both (A-C)
CCR2-GFP+ cells (anti-GFP, green, arrows) with a localization at blood vessel
endothelial cells (lectin, red, arrowheads), as well as (D-F) with a localization
within the parenchyma, consistent with recently infiltrated CCR2-GFP+
monocytes. Of note, lectin can also mark microglia, but at the concentration
used, mostly vessels. (G-H) Confirmatory stainings to show a specific vessel
marker (anti-Collagen-IV; red, arrowheads), with parenchymal localization of
CCR2-GFP+ monocytes in the SNpc (GFP; green, arrows). (Scale bars: F, H,
50 μm). (PDF 3580 kb)
Additional file 8: Figure S7. Induction of CCL2 within astrocytes in
the striatum of MPTP mice. (A) Schematic drawing of the nigro-striatal
pathway of DA neurons. (B-F) Immunofluorescence stainings showing
astrocytic localization (GFAP; green, arrow) of CCL2 induction (red, arrows)
in the striatum (TH, DA innervation; blue) at 24 h after MPTP intoxication (no
staining was detectable in saline injected mice, data not shown). (B) Example
of a cytoplasmic CCL2 staining (shown as a confocal analysis in D-F). (C) Rare
example of a potential extracellular CCL2 staining (red, arrowheads; with
DAPI as a nuclear marker, blue) in close proximity to astrocytic processes
(GFAP; green, arrows); only detected in the striatum, not in the SNpc. Of
note, CCL2 induction was less prominent in the striatum (including at later
timepoints than 24 h, data not shown) than in the SNpc, (see Figs. 2 and 3).
(Scale bars; B, C, F, 20 μm). (PDF 1646 kb)
Additional file 9: Figure S8. Quantitative analysis of presence of CCR2+
monocytes and induction of CCL2 within the striatum of MPTP mice. (A) Full
timecourse analysis of the presence of CCR2-GFP+ cells (inset left; GFP, brown)
within the striatum of MPTP treated CCR2-GFP mice (from 12 h to 7 days
after MPTP intoxication). CCR2-GFP+ cells (inset right) were double-positive
for GFP (green) and cd11b (red), identifying them as monocytes. While there
was a trend for an increase at 36 h after MPTP intoxication, this did not reach
statistical significance (n.s.; P> 0.05; Kruskal-Wallis test). Of note, in contrast to
the striatum, in the substantia nigra, an increased CCR2+ monocyte infiltration
was measured at 36 h after intoxication (see, Fig. 4d). Counts represent
average CCR2-GFP+ cells within a striatal section (means +/− SEM; 5–10
section counted; n= 4 mice per condition). (Scale bar; A, 10 μm). (B) Analysis
of striatal CCR2+ monocyte infiltration in MPTP mice with transgenic over-
induction of astrocytic CCL2. A significant increase in striatal CCR2+ monocyte
infiltration was measured (at 24 h after MPTP intoxication) in CCR2-GFP/
GFAP-CCL2 mice as compared to CCR2-GFP littermates (n= 4 mice per
condition; *P< 0.05; t test). Of note, this was comparable to the significant
increased CCR2+ monocyte infiltration that was detectable (at 24 h after
intoxication) in the substantia nigra of CCR2-GFP/GFAP-CCL2 mice (see,
Fig. 6c). (C) Analysis of striatal astrocytic CCL2 induction in MPTP mice with
deletion for CX3CR1. A significant increased numbers of astrocytes inducing
CCL2 was measured (at 24 h after intoxication) in CX3CR1−/− mice as
compared to wild-type CX3CR1+/+ littermates (n= 4 mice per condition; *P<
0.05; t test). Of note, this was comparable to the significant increased numbers
of astrocytes inducing CCL2 that was detectable in the substantia nigra of
CX3CR1-deleted mice (see, Fig. 7e). (PDF 682 kb)
Additional file 10: Figure S9. Confirmation of CCL2 overexpression in
GFAP-CCL2 mice. (A-C) Immunofluorescence stainings showing that baseline
overexpression of CCL2 (red) in control (saline-injected) GFAP-CCL2/CCR2-GFP
double-transgenic mice is mostly localized around, but less within the SNpc
(A), which is marked with TH (blue). Only very rare CCR2-GFP+ cells (green) are
detected under baseline conditions in or around the SNpc (B). (D-I) Strong
CCL2 induction (red) is detected in the SNpc (marked with TH, blue) of MPTP
treated GFAP-CCL2/CCR2-GFP double transgenic mice (D and inset, G), leading
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to increased presence of CCR2-GFP+ cells (green) in the affected SNpc (E-F
and insets, H-I) (measured at 24 h after intoxication). (Scale bars; B, 200 μm; I,
20 μm). (PDF 1619 kb)
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